AstraZeneca blood clot treatment meets trial endpoint
AstraZeneca on Friday said its Danicopan add-on anti blood-clotting drug had met a primary endpoint in a phase III trial.
AstraZeneca
10,292.00p
16:49 14/11/24
1.46%
148.00p
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
The company said the treatment for paroxysmal nocturnal haemoglobinu (PNH) - a rare, chronic, progressive and potentially life-threatening blood disorder - showed positive high-level results in the trial.
PNH is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis, or blood clots.
Reporting by Frank Prenesti at Sharecast.com